2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06D.02 Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated With Osimertinib

EP.06D.02 Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated With Osimertinib

Back to course

Pdf Summary

This pilot study investigates the use of plasma-derived circulating tumor DNA (ctDNA) to monitor molecular responses and resistance mechanisms in patients with advanced-stage non-small cell lung cancer (NSCLC) harboring EGFR exon 20 mutations (EGFRex20), who are treated with high-dose osimertinib. Previous findings indicated that such a treatment regimen, involving a high dose of 160 mg osimertinib, provided a 28% confirmed response rate with manageable toxicity.<br /><br />The research was conducted by a team from the Departments of Pulmonary Medicine and Pathology at the University of Groningen, The Netherlands. The primary aim was to explore how ctDNA could effectively detect molecular responses and resistance during the course of treatment and at disease progression.<br /><br />The results from this unique cohort demonstrated successful monitoring of responses in all participating patients through the analysis of ctDNA. Moreover, potential resistance mechanisms were identified in 11 out of 18 patients using ctDNA analysis. This suggests that ctDNA can be a valuable tool for tailoring personalized treatment strategies in NSCLC patients with EGFRex20 mutations, helping to identify when adjustments in therapy might be needed due to emerging resistance.<br /><br />This study underscores the promise of ctDNA as a non-invasive biomarker for real-time tracking of treatment efficacy and emergence of resistance, offering insights that could lead to better treatment outcomes for NSCLC patients. The pilot study's findings pave the way for further research to confirm these results in larger patient cohorts and to optimize the use of ctDNA in managing NSCLC.

Asset Subtitle

Anthonie van der Wekken

Meta Tag

Speaker Anthonie van der Wekken

Topic Pathology and Biomarkers

Keywords

plasma-derived ctDNA

molecular responses

resistance mechanisms

advanced-stage NSCLC

EGFR exon 20 mutations

high-dose osimertinib

treatment monitoring

personalized treatment

non-invasive biomarker

real-time tracking